Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study(vol 22, 498, 2022)

被引：0

作者：

Rayer, Cassandra ^{[1
]}

Nachury, Maria ^{[2
]}

Bourreille, Arnaud ^{[3
]}

Roblin, Xavier ^{[4
]}

Peyrin-Biroulet, Laurent ^{[5
]}

Viennot, Stephanie ^{[6
]}

Flamant, Mathurin ^{[7
]}

Laharie, David ^{[8
]}

Caron, Benedicte ^{[5
]}

Dewitte, Marie ^{[1
]}

Siproudhis, Laurent ^{[9
]}

Fumery, Mathurin ^{[10
]}

Bouguen, Guillaume ^{[9
,11
]}

机构：

[1] Univ Rennes, CHU Rennes, F-35000 Rennes, France

[2] Univ Lille, CHU Lille, Lille, France

[3] CHU Nantes, Nantes, France

[4] CHU St Etienne, St Etienne, France

[5] Nancy Univ Hosp, Dept Gastroenterol, Inserm U954 Deparment Hepatogastroenterol, Vandoeuvre Les Nancy, France

[6] CHU Caen, Caen, France

[7] Clin Jules Vernes, Nantes, France

[8] Univ Bordeaux, Hop Haut Leveque, Serv Hepatogastroenterol & Oncol Digest, CHU Bordeaux, F-33000 Bordeaux, France

[9] Univ Rennes, Inst NUMECAN Nutrit Metab & Canc, CHU Rennes, INSERM,CIC 1414, F-35000 Rennes, France

[10] Univ Picardie, Serv Hepatogastroenterol & Oncol Digest, CHU Amiens & PeriTox, UMR I0 I, Amiens, France

[11] Serv Malad Appareil Digest, 2 Rue Henri Le Guillou, F-35033 Rennes, France

来源：

BMC GASTROENTEROLOGY | 2023年 / 23卷 / 01期

关键词：

D O I：

10.1186/s12876-022-02636-9

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页数：1

共 50 条

[1] Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
Cassandra Rayer
Maria Nachury
Arnaud Bourreille
Xavier Roblin
Laurent Peyrin-Biroulet
Stephanie Viennot
Mathurin Flamant
David Laharie
Bénédicte Caron
Marie Dewitte
Laurent Siproudhis
Mathurin Fumery
Guillaume Bouguen
BMC Gastroenterology, 22
[2] Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study
Cassandra, Rayer
Nachury, Maria
Arnaud, Bourreille
Xavier, Roblin
Laurent, Peyrin-Biroulet
Stephanie, Viennot
Mathurin, Flamant
David, Laharie
Benedicte, Caron
Marie, Dewitte
Laurent, Siproudhis
Mathurin, Fumery
Guillaume, Bouguen
BMC GASTROENTEROLOGY, 2022, 22 (01)
[3] Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
Cassandra Rayer
Maria Nachury
Arnaud Bourreille
Xavier Roblin
Laurent Peyrin-Biroulet
Stephanie Viennot
Mathurin Flamant
David Laharie
Bénédicte Caron
Marie Dewitte
Laurent Siproudhis
Mathurin Fumery
Guillaume Bouguen
BMC Gastroenterology, 23
[4] REAL-WORLD COMPARISON OF EFFECTIVENESS BETWEEN USTEKINUMAB AND A SECOND ANTI-TNF AGENT IN PATIENTS WITH SYMPTOMATIC STENOSING CROHN'S DISEASE AFTER FAILURE OF A FIRST ANTI-TNF AGENT: RESULTS OF THE USTEKNOSIS STUDY
Buisson, Anthony
Jammet, Arthur
Pereira, Bruno
Fumery, Mathurin
GASTROENTEROLOGY, 2023, 164 (06) : S648 - S648
[5] Real-world comparison of effectiveness between ustekinumab and a second anti-TNF agent in patients with symptomatic stenosing Crohn's disease after failure of a first anti-TNF agent: results of the USTEKNOSIS study
Buisson, A.
Jammet, A.
Pereira, B.
Fumery, M.
JOURNAL OF CROHNS & COLITIS, 2023, 17 : 562 - 564
[6] Which second-line biologic after anti-TNF failure during Crohn's disease: Ustekinumab or vedolizumab, a multicentre retrospective study
Rayer, C.
Roblin, X.
Laharie, D.
Caron, B.
Flamant, M.
Dewitte, M.
Fumery, M.
Viennot, S.
Bourreille, A.
Pariente, B.
Siproudhis, L.
Peyrin-Biroulet, L.
Bouguen, G.
JOURNAL OF CROHNS & COLITIS, 2020, 14 : S547 - S547
[7] WHICH SECOND-LINE BIOLOGIC AFTER ANTI-TNF FAILURE DURING CROHN'S DISEASE: USTEKINUMAB OR VEDOLIZUMAB, A MULTICENTRE RETROSPECTIVE STUDY
Rayer, Cassandra
Roblin, Xavier
Laharie, David
Flamant, Mathurin
Dewitte, Marie
Fumery, Mathurin
Caron, Benedicte
Viennot, Stephanie
Pariente, Benjamin
Laurent, Siproudhis
Peyrin-Biroulet, Laurent
Bouguen, Guillaume
GASTROENTEROLOGY, 2020, 158 (06) : S958 - S958
[8] Crohn's disease: vedolizumab vs. ustekinumab after anti-TNF pretreatment
Simon, Annika
ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2023, 61 (09): : 1168 - 1170
[9] Effectiveness of anti-TNFα drugs in patients with Crohn's disease who do not achieve remission with their first anti-TNFα agent
del Carmen R-Grau, Maria
Chaparro, Maria
Mesonero, Francisco
Barreiro-de Acosta, Manuel
Castro, Luisa
Castro, Manuel
Domenech, Eugeni
Mancenido, Noemi
Lazaro Perez-Calle, Jose
Taxonera, Carlos
Barrio, Jesus
De Francisco, Ruth
Fernandez-Salgado, Estela
Luzon, Lara
Merino, Olga
Oltra, Lorena
Saro, Cristina
Bermejo, Fernando
Garcia-Sanchez, Valle
Ginard, Daniel
Gutierrez, Ana
Vera, Isabel
Anton, Rosario
Ber, Yolanda
Calvet, Xavier
Gisbert, Javier P.
DIGESTIVE AND LIVER DISEASE, 2016, 48 (06) : 613 - 619
[10] The outcome of Crohn's disease patients refractory to anti-TNF and either vedolizumab or ustekinumab
Kassouri, Liza
Amiot, Aurelien
Kirchgesner, Julien
Treton, Xavier
Allez, Mathieu
Bouhnik, Yoram
Beaugerie, Laurent
Carbonnel, Franck
Meyer, Antoine
DIGESTIVE AND LIVER DISEASE, 2020, 52 (10) : 1148 - 1155

← 1 2 3 4 5 →